Phase II study of cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (NCI # 7097)

BACKGROUND: Inhibition of angiogenesis is a novel strategy for the treatment of cancer. We evaluated the safety and efficacy of cediranib, a potent small molecule inhibitor of the vascular endothelial growth factor receptor, in patients with refractory or recurrent small cell lung cancer (SCLC). MET...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Ramalingam, Suresh S., Belani, Chandra P., Mack, Philip C., Vokes, Everett E., Longmate, Jeffrey, Govindan, Ramaswamy, Koczywas, Marianna, Ivy, S. Percy, Gandara, David R.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2010
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2911495/
https://ncbi.nlm.nih.gov/pubmed/20559150
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0b013e3181e2fcb0
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items